Tag
This study validates the prognostic accuracy of the 15-gene expression profiling (15-GEP) and PRAME assay in uveal melanoma patients irrespective of confirmatory cytopathology, supporting its use in clinical management when cytopathology is
Ocular proton therapy causes significant decreases in corneal nerve fiber parameters in uveal melanoma patients, with partial recovery by 12 months and minimal changes in corneal sensitivity and patient-reported outcomes.
Tumor volume regression at one year post-I-125 plaque brachytherapy significantly predicts overall survival in posterior uveal melanoma, with intermediate regression showing the best outcomes.
A large French case series found pathogenic or likely pathogenic germline MBD4 variants in 23 of 896 patients with uveal melanoma, corresponding to a 31-fold relative risk versus the general population.
